|Bid||0.2750 x 78655600|
|Ask||0.2500 x 42535300|
|Day's range||0.2700 - 0.2800|
|52-week range||0.2500 - 0.5900|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 27 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||03 Mar 2011|
|1y target est||0.42|
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets). Mayne Pharma anticipates the commercial launch of NEXTSTELLIS by mid-2022 supported by healthcare professional market education from January 2022.
We feel now is a pretty good time to analyse Mayne Pharma Group Limited's ( ASX:MYX ) business as it appears the...